Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Gene Transfer for Cancer Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00804076
Recruitment Status : Completed
First Posted : December 8, 2008
Last Update Posted : February 19, 2014
Information provided by (Responsible Party):
Diamyd Inc

Brief Summary:
The primary purpose of this study is to examine the safety of NP2 (a nonreplicating HSV-based vector expressing enkephalin) in patients with cancer pain. The secondary purpose is to evaluate efficacy.

Condition or disease Intervention/treatment Phase
Cancer Pain Biological: NP2 Phase 1

Detailed Description:
Therapeutic HSV-based vectors deliver genes from skin inoculation to sensory neurons to interrupt pain signaling at the spinal level. Side effects may be limited by the focal distribution of vector delivery and preproenkephalin expression. Preproenkephalin is a natural human gene that produces peptides that bind to opioid receptors in the body. The therapeutic being evaluated, NP2, is a replication defective herpes simplex type 1 virus (HSV-1) modified to express the human preproenkephalin gene that has demonstrated efficacy in numerous model of pain, including pain caused by cancer.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Gene Transfer for Intractable Pain: A Phase I Clinical Trial to Determine the Maximum Tolerable Dose of a Replication-Defective Herpes Simplex Virus Type I (HSV-1) Vector Expressing Human Preproenkephalin (NP2) in Patients With Malignancies
Study Start Date : February 2008
Actual Primary Completion Date : November 2010
Actual Study Completion Date : July 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: NP2
Intradermal injection
Biological: NP2
Intradermal injection of NP2 at doses ranging from 10e7 to 10e9 pfu at the site of pain.

Primary Outcome Measures :
  1. Safety measured by vital signs, physical exam findings, clinical laboratory analyses and treatment related Adverse Events (AE). [ Time Frame: 4 Months ]

Secondary Outcome Measures :
  1. Evaluate changes in cancer-related pain [ Time Frame: 4 Months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with intractable pain from malignant disease with a 5 year projected survival of less than 25%.
  2. Female patients of childbearing potential who have a negative pregnancy test and using birth control.
  3. Patients who have not received recent treatment with a radiation, chemotherapeutic or immunotherapeutic agent and are not expected to undergo such treatment 28 days after injection of NP2.
  4. Patients who have not had surgical stabilization/resection within 4 weeks of Screening and have no plans for additional surgical procedures.
  5. Patients with adequate bone marrow function, IgG levels greater than 565 mg% and CD4 count greater than 500. .

Exclusion Criteria:

  1. Patients with serious uncontrolled medical conditions other than malignancy.
  2. Patients with severe liver or renal impairment
  3. Patients currently or previously with positive serology for HIV, Hepatitis B or Hepatitis C.
  4. Patients with a hemoglobin <9 gm% or uncontrolled coagulopathy or bleeding diathesis.
  5. Patients with a clinical diagnosis of any active herpes infection within the past 6 months.
  6. Patients who have been vaccinated to prevent HSV infection or a history of shingles or the presence of active shingles.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00804076

Layout table for location information
United States, Florida
Advanced Pharma CR
Miami, Florida, United States, 33175
United States, Louisiana
Louisiana Research Associates
New Orleans, Louisiana, United States, 70114
United States, Michigan
University of Michigan Medical Center
Ann Arbor, Michigan, United States, 49109
United States, North Carolina
Center for Clinical Research
Winston-Salem, North Carolina, United States, 27103
United States, Oregon
Pain Research of Oregon, LLC
Eugene, Oregon, United States, 97401
Sponsors and Collaborators
Diamyd Inc
Layout table for investigator information
Principal Investigator: David J Fink, MD University of Michigan Department of Neurology

Layout table for additonal information
Responsible Party: Diamyd Inc Identifier: NCT00804076    
Other Study ID Numbers: NP2/P1/07/1
First Posted: December 8, 2008    Key Record Dates
Last Update Posted: February 19, 2014
Last Verified: February 2014
Keywords provided by Diamyd Inc:
gene therapy
replication defective HSV vector
Additional relevant MeSH terms:
Layout table for MeSH terms
Cancer Pain
Neurologic Manifestations
Signs and Symptoms